[go: up one dir, main page]

RU99118887A - APPLICATION OF GASTROINTESTINAL LIPASE INHIBITORS - Google Patents

APPLICATION OF GASTROINTESTINAL LIPASE INHIBITORS

Info

Publication number
RU99118887A
RU99118887A RU99118887/14A RU99118887A RU99118887A RU 99118887 A RU99118887 A RU 99118887A RU 99118887/14 A RU99118887/14 A RU 99118887/14A RU 99118887 A RU99118887 A RU 99118887A RU 99118887 A RU99118887 A RU 99118887A
Authority
RU
Russia
Prior art keywords
gastrointestinal lipase
application
lipase inhibitors
gastrointestinal
inhibitor
Prior art date
Application number
RU99118887/14A
Other languages
Russian (ru)
Other versions
RU2201272C2 (en
Inventor
Джонатан Брайан ХОПТМАН
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU99118887A publication Critical patent/RU99118887A/en
Application granted granted Critical
Publication of RU2201272C2 publication Critical patent/RU2201272C2/en

Links

Claims (4)

1. Применение ингибитора желудочно-кишечной липазы для приготовления лекарственных средств, назначаемых орально, для лечения или предупреждения сахарного диабета типа II.1. The use of a gastrointestinal lipase inhibitor for the preparation of orally prescribed drugs for the treatment or prevention of type II diabetes mellitus. 2. Применение по п.1, где ингибитор желудочно-кишечной липазы представляет собой тетрагидролипстатин. 2. The use according to claim 1, where the inhibitor of the gastrointestinal lipase is tetrahydrolipstatin. 3. Лекарственное средство для орального введения, предназначенное для лечения или предупреждения сахарного диабета типа II, отличающееся тем, что оно содержит эффективное количество ингибитора желудочно-кишечной липазы. 3. A medicament for oral administration intended for the treatment or prevention of type II diabetes mellitus, characterized in that it contains an effective amount of a gastrointestinal lipase inhibitor. 4. Лекарственное средство для орального введения по п.3, где ингибитор желудочно-кишечной липазы представляет собой тетрагидролипстатин. 4. The oral drug of claim 3, wherein the gastrointestinal lipase inhibitor is tetrahydrolipstatin.
RU99118887/14A 1997-02-05 1998-01-29 Application of inhibitors of gastro- intestinal lipase RU2201272C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3738397P 1997-02-05 1997-02-05
US60/037,383 1997-02-05

Publications (2)

Publication Number Publication Date
RU99118887A true RU99118887A (en) 2001-05-20
RU2201272C2 RU2201272C2 (en) 2003-03-27

Family

ID=21894047

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99118887/14A RU2201272C2 (en) 1997-02-05 1998-01-29 Application of inhibitors of gastro- intestinal lipase

Country Status (27)

Country Link
US (1) US6147108A (en)
EP (1) EP1017408B1 (en)
JP (1) JP2001509173A (en)
KR (1) KR100479968B1 (en)
CN (1) CN1154505C (en)
AR (1) AR011106A1 (en)
AT (1) ATE292975T1 (en)
AU (1) AU740375B2 (en)
BR (1) BR9807655A (en)
CA (1) CA2278854C (en)
CZ (1) CZ295567B6 (en)
DE (1) DE69829763T2 (en)
DK (1) DK1017408T3 (en)
ES (1) ES2239799T3 (en)
HU (1) HU230834B1 (en)
ID (1) ID22650A (en)
IL (1) IL131007A0 (en)
ME (1) ME00578A (en)
NO (1) NO324452B1 (en)
NZ (1) NZ336755A (en)
PL (1) PL191222B1 (en)
PT (1) PT1017408E (en)
RU (1) RU2201272C2 (en)
TR (1) TR199901853T2 (en)
WO (1) WO1998034630A1 (en)
YU (1) YU34199A (en)
ZA (1) ZA98753B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239799T3 (en) * 1997-02-05 2005-10-01 F. Hoffmann-La Roche Ag USE OF TETRAHIDROLIPSTATIN IN THE TREATMENT OF TYPE II DIABETES.
AR025609A1 (en) 1999-09-13 2002-12-04 Hoffmann La Roche SOLID LIPID FORMULATIONS
AR025587A1 (en) * 1999-09-13 2002-12-04 Hoffmann La Roche DISPERSION FORMULATIONS CONTAINING LIPASA INHIBITORS
ATE428733T1 (en) 2000-03-14 2009-05-15 Unilever Nv VARIABLE DOMAIN OF THE HEAVY CHAIN OF AN ANTIBODY TO HUMAN NUTRITIONAL LIPASES AND THEIR USES
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US9174176B2 (en) 2003-01-09 2015-11-03 Disperse Systems, Inc. Ultrasonic dispersion apparatus, system, and method
RU2248793C1 (en) * 2003-11-13 2005-03-27 Лазебник Леонид Борисович Method for treating steatohepatitis
US7510849B2 (en) * 2004-01-29 2009-03-31 Glucolight Corporation OCT based method for diagnosis and therapy
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
US8036727B2 (en) 2004-08-11 2011-10-11 Glt Acquisition Corp. Methods for noninvasively measuring analyte levels in a subject
US7254429B2 (en) 2004-08-11 2007-08-07 Glucolight Corporation Method and apparatus for monitoring glucose levels in a biological tissue
WO2006110859A2 (en) 2005-04-13 2006-10-19 Glucolight Corporation Method for data reduction and calibration of an oct-based blood glucose monitor
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
EP2036575B1 (en) * 2007-09-12 2010-08-18 Mader S.r.l. Pharmaceutical compositions for oral use for treating patients affected by obesity
WO2009050720A1 (en) * 2007-10-15 2009-04-23 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
KR101234540B1 (en) 2007-10-16 2013-02-19 바이오콘 리미티드 An orally administerable solid pharmaceutical composition and a process thereof
US8571617B2 (en) 2008-03-04 2013-10-29 Glt Acquisition Corp. Flowometry in optical coherence tomography for analyte level estimation
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
FR3017536B1 (en) * 2014-02-18 2017-05-26 Univ La Rochelle COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF ALPHA GLUCOSIDASE PATHOLOGIES
CN109414414A (en) 2016-03-16 2019-03-01 戴维·格拉德斯通研究所 Method and composition for treating obesity and/or diabetes and for identifying candidate therapeutic agent
WO2019018849A1 (en) * 2017-07-21 2019-01-24 Kieu Hoang Statins (atorvastatin) can lower blood sugar level in diabetic

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5345056A (en) * 1991-12-12 1994-09-06 Motorola, Inc. Plasma based soldering by indirect heating
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
JP3532999B2 (en) * 1995-03-24 2004-05-31 株式会社ロッテ Novel tannins and lipase inhibitors containing them as active ingredients
JPH09227398A (en) * 1996-02-20 1997-09-02 Zeria Pharmaceut Co Ltd Antiobesity agent
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
ES2239799T3 (en) * 1997-02-05 2005-10-01 F. Hoffmann-La Roche Ag USE OF TETRAHIDROLIPSTATIN IN THE TREATMENT OF TYPE II DIABETES.

Similar Documents

Publication Publication Date Title
RU99118887A (en) APPLICATION OF GASTROINTESTINAL LIPASE INHIBITORS
CA2214033A1 (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
CA2186039A1 (en) New oral pharmaceutical dosage form
SE9600070D0 (en) New oral pharmaceutical dosage forms
AR014467A1 (en) ORMALLY ADMINISTRABLE PHARMACEUTICAL DOSE UNIT OF A SIZE HIGHER THAN 7 MM THAT INCLUDES A DRUG AND EXTERNAL COATING, A METHOD TO PARASEPAR AN ORALLY ADMINISTRABLE PHARMACEUTICAL DOSE UNIT FROM A DIFFERENT CO-ADMINISTRATED FOOD AND USE COVER
CA2106172A1 (en) Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention
DE69832816D1 (en) ORAL PHARMACEUTICAL DOSAGE FORM WITH EXTENDED DRUG RELIEF
CA2382387A1 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
BR9807655A (en) Use of gastrointestinal lipase inhibitors.
HUP9802795A2 (en) Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence
CA2377174A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
BE901073A (en) ANTIDIURETIC COMPOSITION FOR ORAL USE.
RU2001107149A (en) TAUROLIDINE AND / OR TAURULTS AGAINST INFECTIOUS ULCER DISEASE OR INFECTIOUS GASTRITIS
EP0375628A3 (en) Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
RU98116126A (en) PHARMACEUTICAL COMBINED DRUG FROM INHIBITOR OF SODIUM-HYDROGEN METABOLISM AND MEDICINES FOR TREATMENT OF CARDIOVASCULAR DISEASES
EP0657167A3 (en) Use of oenotheine B for the manufacture of a medicament for the treatment of disorders related to hyperandrogenism, pharmaceutical compositions containing oenotheine B and a process for its preparation from epilobium parviflorum.
EP1295875A4 (en) Heterocyclic compounds
HUP0001104A2 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
HK1046089A1 (en) Therapeutic use of melatonin
DZ2564A1 (en) Pharmaceutical compositions for the treatment of diabetes mellitus and associated conditions.
RU2004112422A (en) ROUVASTATIN IN PREDEDENTIONAL CONDITIONS
KR870009716A (en) Chlorfeniramine Formulation